Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Next Previous
Trial Profile

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Fulvestrant (Primary) ; MRT-2359 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Diffuse large B cell lymphoma; HER2 negative breast cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Monte Rosa Therapeutics

Most Recent Events

  • 20 Mar 2025 According to a Monte Rosa Therapeutics media release, Scompany will share additional MRT-2359 Phase 1/2 study data in CRPC patients resistant to AR therapy in H2 2025, while deprioritizing further expansion arms in SCLC, NSCLC and NE tumors
  • 20 Mar 2025 Results presented in the Monte Rosa Therapeutics Media Release.
  • 11 Mar 2025 According to a Monte Rosa Therapeutics media release, company announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors in a conference call and webcast are planned for Thursday, March 20, 2025, at 8:00 a.m. ET.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top